“…Furthermore, the monoclonal antibodies targeting the molecular markers on human lymphocytes, e.g., alemtuzumab (anti-CD52 antibody) and thymoglobulin, cannot be used as induction agents in animals. Despite these limitations, however, animals are still useful for building a surgical model of small bowel transplantation [14][15][16][17][18]22].…”